# Eunice S. Wang

Source: https://onco.cc/people/eunice-wang/  
OnCo record `eunice-wang` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Eunice Wang is an AML trialist who helped bring FLT3 and menin inhibitors to patients.

## Summary

Eunice S. Wang is Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center. She is an acute myeloid leukaemia trialist known for helping bring FLT3 inhibitors and menin inhibitors to patients, as an investigator on gilteritinib, quizartinib and revumenib studies. Her selected paper reviews crenolanib for FLT3-mutated AML. She leads leukaemia clinical research at Roswell Park and serves on the NCCN acute myeloid leukaemia guideline panel.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Chief, Leukemia Service
- Specialisms: Acute myeloid leukaemia; FLT3 inhibitors; Novel leukaemia agents

## Sources

- Roswell Park profile: https://www.roswellpark.org/eunice-wang
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20ES%5BAuthor%5D

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- targets: [FLT3](https://onco.cc/targets/flt3/), [Menin](https://onco.cc/targets/menin/)
- drugs: [Gilteritinib](https://onco.cc/drugs/gilteritinib/), [Revumenib](https://onco.cc/drugs/revumenib/)
- institutions: [Roswell Park Comprehensive Cancer Center](https://onco.cc/institutions/roswell-park/)
- journals: [Blood Advances](https://onco.cc/journals/blood-advances/)

---
JSON: https://onco.cc/api/v1/entities/eunice-wang.json